Rrapese G, Mazzucchelli L, et al: Multideterminants analysis of molecular alterations for predicting clinical advantage to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4(ten):e7287. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A: The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277(5324):33338. Buhrman G, Wink G, Mattos C: Transformation efficiency of RasQ61 mutants linked to structural capabilities in the switch regions in the presence of Raf. Structure 2007, 15(12):1618629. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, et al: Genomic and biological characterization of exon four KRAS mutations in human cancer. Cancer Res 2010, 70(14):5901911. Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991, 349(6305):11727. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Superior VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al: Mechanism of activation of your RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):85567. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005, 65(11):4562567. Samuels Y, Wang ZH, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell DM, Riggins GJ, et al: Higher frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells.Estramustine Cancer Cell 2005, 7(six):56173.Guedes et al. BMC Cancer 2013, 13:169 http://www.biomedcentral/1471-2407/13/Page 10 of45. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, SchneidmanDuhovny D, Wolfson HJ, Backer JM, Williams RL: Mechanism of two classes of cancer mutations within the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317(5835):23942. 46. Gymnopoulos M, Elsliger MA, Vogt PK: Uncommon cancer-specific mutations in PIK3CA show acquire of function. Proc Natl Acad Sci USA 2007, 104(13):5569574. 47. Zhao L, Vogt PK: Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce acquire of function by diverse mechanisms. Proc Natl Acad Sci USA 2008, 105(7):2652657. 48. Kang SY, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.Alirocumab Proc Natl Acad Sci USA 2005, 102(3):80207.PMID:23551549 49. Bader AG, Kang SY, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5(12):92129. 50. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM: The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318(5857):1744748. 51. Mao C, Liao RY, Qiu LX, Wang XW, Ding H, Chen Q: BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in individuals with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011, 38(four):2219223.doi:ten.1186/1471-2407-13-169 Cite this short article as: Guedes et al.: High resolution melting evaluation of KRAS, BRAF and PIK3CA in KRAS exon two wild-type metastatic colorectal cancer. BMC Canc.
